Benjamin Hanfstein - Concepedia

Author

Benjamin Hanfstein

Heidelberg University

Also Known As

B Hanfstein, B. Hanfstein, Benjamin Hanfstein, Eva Lengfelder, Martin C. Müller, Martine Jotterand, Ulrike Proetel

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Heidelberg University University Hospital Heidelberg Jena University Hospital Medizinische Fakultät Mannheim Munich Leukemia Laboratory (Germany)

About

Benjamin Hanfstein is an author at Heidelberg University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	2K
2	Cell Biology	9	9	1.6K
3	Health Sciences	7	7	845
4	Engineering	1	1	135
5	Public Health	1	1	50

Benjamin Hanfstein

Publications

Citations

H-Index

Page 1

	Year	Citations
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Andreas Hochhaus, Sebastian Kreil, A. Corbin, Leukemia ChromatinGenome InstabilityCell DivisionCytogeneticsChromatin Remodeling	2002	900
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann, Leukemia Hematological MalignancyChronic Myeloid LeukemiaHealth SciencesMedicineHematology	2012	416
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV Rüdiger Hehlmann, Martin C. Müller, Michael Lauseker, Journal of Clinical Oncology	2013	296
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV Alice Fabarius, Armin Leitner, Andreas Hochhaus, Blood	2011	286
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV Lida Kalmanti, Michael Lauseker, M. C. Muller, Leukemia Hematological MalignancyOncologyClinical TrialsMyeloid NeoplasiaCml-study Iv	2015	273
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV Susanne Saußele, Marie-Paloma Krauß, Rüdiger Hehlmann, Blood	2015	197
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib Benjamin Hanfstein, Valeria Shlyakhto, Michael Lauseker, Leukemia Chronic PhaseHematological MalignancyChronic Myeloid LeukemiaOncologyOptimized Predictor	2014	135
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV Manuel Barreto Miranda, Michael Lauseker, M-P Kraus, Leukemia	2016	87
KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer Philipp Erben, Philipp Ströbel, Karoline Horisberger, International Journal of Radiation OncologyBiologyPhysics Radiation TherapyGastrointestinal OncologyPten Expression DoBraf MutationsMedicine	2010	54
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy Benjamin Hanfstein, Martin C. Müller, Sebastian Kreil, Haematologica	2010	52

Page 1